B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy - Woyach, Jennifer A. (The Ohio State University Comprehensive Cancer Center, Columbus, Ohio) ; Ghia, Paolo (Universita Vita-Salute San Raffaele, Milan, Italy) ; Byrd, John C. (University of Cincinnati College of Medicine, Cincinnati, Ohio) ; Ahn, Inhye E. (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland) ; Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Brien, Susan M. (UC Irvine. Chao Family Comprehensive Cancer Center, Irvine, California) ; Jones, Daniel (The Ohio State University Comprehensive Cancer Center, Irvine, California) ; Cheung, Leo W.K. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Chong, Elizabeth (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Kwei, Kevin (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Dean, James P. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; James, Dannelle F. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Wiestner, Adrian (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland)